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Introduction {#sec1}
============

In normal cells, the BRAF kinase, encoded by the *BRAF* gene, is a critical effector of cell signaling pathways, most notably the RAS-BRAF-MEK-ERK mitogenic pathway. This proto-oncogenic pathway is activated by genetic mutations at some point along the cascade in most human cancers ([@bib52]). Approximately 10% of human CRC are associated with activated *BRAFV600E* mutation. Although inhibitors of activated BRAF, such as Vemurafenib, are of some benefit in other cancers harboring *BRAFV600E*, such as melanoma, in CRC these inhibitors are of limited therapeutic value ([@bib9]). Yet CRC harboring *BRAFV600E* has a poor prognosis ([@bib43], [@bib39]). Thus, it is important to understand the oncogenic mechanisms underlying this disease.

Activated *BRAFV600E* mutation is typically found in absence of mutation in the *Adenomatous Polyposis Coli* (*APC*) gene, a gene that is mutated and inactivated in ∼80% of CRC ([@bib9]). Activated BRAFV600E drives hyperproliferation and neoplasia via the MEK-ERK mitogenic pathway ([@bib29]). However, to protect from cancer, normal intestinal epithelial cells are thought to respond to oncogenic BRAFV600E by activation of intrinsic *TP53* (p53) and *CDKN2A* (p16)-dependent tumor suppressor mechanisms ([@bib41]), including cellular senescence ([@bib4], [@bib25]). In response to acquisition of an activated oncogene, primary human cells can enter a proliferation-arrested senescent state (oncogene-induced senescence \[OIS\]) that suppresses tumor formation ([@bib35], [@bib5], [@bib2], [@bib6], [@bib20]). Senescent cells also exhibit an altered secretory program, the so-called Senescence Associated Secretory Phenotype (SASP) ([@bib27], [@bib1], [@bib26]) comprised of pro-inflammatory cytokines and chemokines, which also contributes to tumor suppression by promoting clearance of senescent cells by the immune system ([@bib32], [@bib50], [@bib24]).

Conversely, CpG island methylator phenotype (CIMP) is thought to contribute to bypass of tumor suppressor mechanisms by epigenetic silencing of tumor suppressor genes, such as *MLH1* and *CDKN2A* ([@bib28]). In CRC, *BRAFV600E* mutation and CIMP are quite tightly linked ([@bib39], [@bib49], [@bib23], [@bib36], [@bib37], [@bib21], [@bib3]), leading to speculation that BRAFV600E promotes and/or selects for CIMP *en route* to tumor progression. Because *CDKN2A* encodes p16, a key effector of cellular senescence ([@bib20]), CIMP might be expected to suppress OIS.

DNA methyl transferase 3B (DNMT3B) is a so-called *de novo* DNA methyl transferase, capable of methylating CpGs where both CpGs of the palindrome are in the unmethylated state. In normal mouse intestine, inactivation of Dnmtb does not have a marked phenotype ([@bib11], [@bib30]). However, several studies have suggested that elevated DNMT3B might cooperate with BRAFV600E to drive tumorigenesis and that DNMT3B is responsible for methylation of DNA to generate CIMP ([@bib4], [@bib12], [@bib22], [@bib38]). According to one model in which the link between oncogene activation and CIMP can be quite indirect, oncogene-induced senescence and/or other oncogene-activated p53 and p16-dependent tumor suppressor mechanisms provide the selective pressure for DNMT3B and CIMP-mediated silencing of these key tumor suppressor pathways. Consistent with this model, in a mouse model of BrafV600E-driven colon cancer, escape from senescence and tumor progression was linked to increased expression of Dnmt3b and methylation and silencing of p16 ([@bib4]). According to this model, although activated BRAFV600E can increase the selective pressure that favors CIMP, methylation is not directly caused by BRAFV600E but has an inherent tendency to encroach on unmethylated CpG islands during aging ([@bib44], [@bib47], [@bib46]). In another model that more directly links oncogenic signaling and CIMP, it has been proposed that BRAFV600E signaling recruits DNMT3B to genes silenced by CIMP via the transcriptional repressor, MAFG, thereby directly promoting CIMP ([@bib12], [@bib13]).

However, studies into the relationship between BRAFV600E and DNMT3B to this point are incomplete. For example, their associations in human TCGA data and functional interactions in mouse models have not, as far as we are aware, been considered in detail in previous studies. Here we set out to investigate whether BRAFV600E and DNMT3B cooperate in intestinal tumorigenesis by examination of human tumor data, *in vitro* models of senescence, and mouse models of CRC. The results present a mixed story, but are important for the field, and, on balance, lead us to suggest that *BRAFV600E* mutation and DNMT3B do not frequently cooperate to promote CIMP and human intestinal cancer.

Results {#sec2}
=======

*DNMT3B* Is Frequently Amplified and Overexpressed in Human CRC {#sec2.1}
---------------------------------------------------------------

To begin to probe the putative oncogenic function of DNMT3B in human CRC, we mined human TCGA data examining levels of *DNMT3B* expression and gene copy number. First, we confirmed that, at the mRNA level, *DNMT3B* is expressed at a higher level in human CRC than normal human colon ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). We also found that the *DNMT3B* gene exhibits increased copy number, indicative of gene amplification, in a substantial proportion of CRC ([Figure 1](#fig1){ref-type="fig"}B). Amplification of *DNMT3B* in human CRC is also apparent via Database: [cbioportal.org](http://cbioportal.org){#intref0010} ([@bib15]). Moreover, comparing *DNMT3B* mRNA expression and gene copy number revealed a correlation between *DNMT3B* copy number and mRNA expression ([Figures 1](#fig1){ref-type="fig"}C and 1D). These data are consistent with the idea that increased DNMT3B expression can be oncogenic and suggest that increased expression in human CRC is often a result of gene amplification.Figure 1*DNMT3B* Is Frequently Amplified and Overexpressed in CRC(A) Violin plot showing distribution of *DNMT3B* expression levels in 207 CRC tumor samples. Mann-Whitney U test; p value = 5.785e-10.(B) *DNMT3B* relative copy number across 207 tumor samples. Lines at y axis −0.2 and 0.2 indicate the threshold for deletion and amplification, respectively.(C) Median centered log2 *DNMT3B* mRNA expression plot from 207 tumor samples (TCGA) annotated with BRAF mutation status.(D) The relationship between *DNMT3B* relative copy number and *DNMT3B* mRNA expression in 207 tumor samples.

Ectopic Expression of DNMT3B Antagonizes BRAFV600E-Induced Proliferation Arrest and SASP {#sec2.2}
----------------------------------------------------------------------------------------

Previous studies suggested that elevated DNMT3B might cooperate with BRAFV600E to drive tumorigenesis ([@bib4], [@bib12], [@bib22], [@bib38]). To investigate this possibility of oncogenic cooperation between BRAFV600E and elevated DNMT3B, we tested functional interactions between the two in an *in vitro* cell culture model. In the absence of a robust normal human colonic epithelial cell model, we turned to primary human fibroblasts that were previously used to model molecular events underlying CIMP in CRC ([@bib12]) and more generally have been a paradigm for investigating mechanisms of oncogene cooperation in human cells ([@bib18], [@bib19]). Primary human IMR90 fibroblasts were infected with drug-selectable lentiviruses directing expression of BRAFV600E, DNMT3B, or empty vector as a control. Both proteins were efficiently expressed for up to 10 days post-infection ([Figure 2](#fig2){ref-type="fig"}A). When expressed on its own, activated BRAFV600E induced a marked decrease in the percent of cells in S phase of the cell cycle, in line with this oncogene\'s ability to induce senescence-associated proliferation arrest in primary cells ([@bib35], [@bib40]) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The decline in cells in S phase was accompanied by decreased abundance of cell cycle drivers, cyclin A, and phosphorylated pRB, and, perhaps accounting for decreased phosphorylated pRB through regulation of p16INK4A ([@bib33]), decreased expression of EZH2 ([Figure 2](#fig2){ref-type="fig"}A). Ectopic expression of DNMT3B increased the proportion of cells in S phase, proportionately more so in cells ectopically expressing BRAFV600E ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). In cells expressing both BRAFV600E and DNMT3B compared with those expressing BRAFV600E only, this was accompanied by increased cyclin A, EZH2 and phosphorylated pRB, and, at the seven-day time point, a consistent decrease in expression of cell cycle inhibitor, CDKN1B (p27KIP1) ([Figure 2](#fig2){ref-type="fig"}A). Expression of DNMT3B alone had no detectable effect on these key cell-cycle regulators ([Figure 2](#fig2){ref-type="fig"}A). We conclude that elevated DNMT3B antagonizes BRAFV600E-induced cell-cycle arrest.Figure 2DNMT3B Suppresses Features of OIS(A) Kinetic analysis assessing the impact of ectopic DNMT3B on markers of BRAFV600E-induced cell-cycle exit of primary IMR90 cells, determined by Western blot. MW markers in kDa.(B) Impact of ectopic DNMT3B on BRAFV600E-induced S-phase exit of primary IMR90 cells, determined by BrdU labeling. Each group n = 4, from days 3, 5, 7, and 10 post-infection. Middle line = median; box top/bottom = upper and lower quartiles; whiskers 90^th^ (upper) & 10^th^ (lower) percentile of data. Kruskal-Wallis test, p \< 0.05.(C) Number of significantly differentially expressed genes between indicated pairwise comparisons of primary IMR90 cells expressing ectopic BRAFV600E and/or DNMT3B and/or empty vectors, determined from RNA-seq FPKM values (Cuffdiff, FDR corrected p value of \<0.05).(D) Number of significantly up or down genes between indicated pairwise comparisons of primary IMR90 cells expressing ectopic BRAFV600E and/or DNMT3B and/or empty vectors, determined from RNA-seq FPKM values.(E) Heatmap of expression of significant changed proliferation-associated genes.(F) Heatmap of expression of significant changed SASP genes.

To better understand the effect of DNMT3B on BRAFV600E-induced cell-cycle arrest, we infected cells with empty vector, DNMT3B alone, BRAFV600E alone, or the combination and performed RNA-seq. Principal component analysis showed that three replicates of each condition expressed distinct transcriptomes ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Expression of activated BRAFV600E significantly increased and decreased expression of 3403 and 5745 genes, respectively ([Figures 2](#fig2){ref-type="fig"}C and 2D). These changes in gene expression include those characteristic of OIS, including repression of cell cycle genes and activation of inflammatory genes indicative of the SASP ([Figures 2](#fig2){ref-type="fig"}E and 2F). However, co-expression of DNMT3B antagonized a substantial proportion of the gene expression changes induced by BRAFV600E ([Figure 2](#fig2){ref-type="fig"}D) (specifically, 1,055 of genes upregulated by BRAFV600E and 2,546 of genes downregulated by BRAFV600E). Consistent with the previous cell-cycle analyses ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}A), DNMT3B modestly suppressed BRAFV600E-induced repression of many cell proliferation genes ([Figures 2](#fig2){ref-type="fig"}E, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). In addition, DNMT3B markedly suppressed many of the SASP genes induced by BRAFV600E ([Figure 2](#fig2){ref-type="fig"}F). DNMT3B-mediated suppression of BRAFV600E-induced repression of cell-cycle genes and activation of SASP was also apparent by GSEA analysis ([Figure S2](#mmc1){ref-type="supplementary-material"}E). In sum, elevated DNMT3B impaired two key tumor suppressive phenotypes induced by BRAFV600E in primary human cells, cell-cycle arrest and SASP. These data show that combined expression of BRAFV600E and DNMT3b could cooperate to promote tumorigenesis.

Dnmt3b Enhances Tumorigenesis and Decreases Survival in a BrafV600E-Driven Mouse Model of Intestinal Cancer {#sec2.3}
-----------------------------------------------------------------------------------------------------------

To investigate the tumor promoting potential of combined BrafV600E mutation and elevated Dnmt3b *in vivo*, we tested the two in an *in vivo* mouse model of intestinal tumorigenesis. A previous study reported that mouse intestinal-specific expression of activated Braf under control of a constitutive villin-Cre recapitulates features of the human serrated pathway of intestinal tumorigenesis ([@bib41]). In an effort to better mimic cancer initiation in human adult tissues, in a modified version of this model, mice expressing a conditional-activated intestinal-specific *BrafV600E* oncogene under the control of tamoxifen-inducible *Villin-Cre-ERT2* were crossed to mice expressing conditional *Dnmt3b* under control of doxycycline inducible rtTA ([@bib10], [@bib31], [@bib45]). Transgene expression was induced in 6- to 10-week-old mice, and western blotting confirmed inducible expression of Dnmt3b in the small intestine and colon ([Figure 3](#fig3){ref-type="fig"}A). Mice were culled when they showed comparable clinical signs of disease. Accordingly, at the time the BrafV600E and BrafV600E/Dnmt3b mice were culled, the two groups harbored a comparable number of small intestinal tumors ([Figures 3](#fig3){ref-type="fig"}B and 3C); no overt differences in tumor histology were noted between BrafV600E and BrafV600E/Dnmt3b tumors. No colonic tumors were identifiable in any mice examined. At this time, we did not detect any overt differences between proliferation and senescence markers in BrafV600E/Dnmt3b and BrafV600E mice, in either tumor or histologically normal intestine ([Figures 3](#fig3){ref-type="fig"}D, 3E, and [S3](#mmc1){ref-type="supplementary-material"}A and data not shown). Strikingly, however, combined ectopic Dnmt3b expression together with activated BrafV600E in the murine intestine resulted in a marked decrease in overall survival compared with BrafV600E alone ([Figure 3](#fig3){ref-type="fig"}F). Median post-survival induction in mice expressing BrafV600E and endogenous Dnmt3b was 489 days, compared with 289 in mice with ectopic BrafV600E and Dnmt3b. Mice expressing ectopic Dnmt3b alone did not develop any clinical signs of illness up until 377 days following induction and were culled at this time. Neither intestinal abnormalities nor tumors were identified in these mice, consistent with previous reports ([@bib45], [@bib31]). These results suggest that elevated Dnmt3b accelerated the accumulation of a lethal burden of BrafV600E-driven intestinal tumors.Figure 3DNMT3B Accelerates Intestinal Cancer(A) Western blot showing doxycycline-inducible expression of Dnmt3b in small intestine (S) and colon (C) of *R26-M2-rtTA;Col1a1-tetO-*Dnmt3b1 and *R26-M2-rtTA;WT* mice. MW markers in kDa.(B) Number of small intestine tumors in *VilCreErT2;LSL B*raf*V600E* mice with and without ectopic Dnmt3b expression. Mean with error bars −/+ SEM. Mann Whitney test p = 0.98 (ns) n = 5 vs 5.(C) Representative small intestine tumor from*VilCreErT2;LSL B*raf*V600E* mice, similar with or without Dnmt3b.(D) Representative immunohistochemistry images for Ki67 in *VilCreErT2*; *LSLB*raf*V600E* mice with and without ectopic Dnmt3b. Scale bars are 200 μM.(E) Representative immunohistochemistry images for p21 in *VilCreErT2*;*LSLB*raf*V600E* mice with and without ectopic Dnmt3b. Scale bars are 200 μM.(F) Kaplan-Meier curve comparing survival in *VilCreErT2; LSLB*raf*V600E* mice with and without intestinal Dnmt3b ectopic expression. "DNMT3B only" mice ("*Col1a1-tetO-Dnmt3b1* +/−") also shown. Log rank (Mantel-Cox) test, p \< 0.0001.(G) Total small intestine tumor number in *VilCreErT2; LSLB*raf*V600E; D*nmt3b*^wt/wt^* and *VilCreErT2; LSLB*raf*V600E; D*nmt3b^fl/fl^ mice. Mann Whitney test p = 0.42; n = 5 vs 5. Mean with error bars −/+ SEM.(H) Kaplan-Meier curve of survival in *VilCreErT2;LSLB*raf*V600E* mice with wild-type or floxed *D*nmt3b. Log Rank (Mantel-Cox) test, p \< 0.02.

To test whether Dnmt3b is required for BrafV600E-induced intestinal tumorigenesis, we generated mice harboring a conditionally activated *BrafV600E* oncogene and conditionally inactivated *Dnmt3b^fl/fl^*, both under control of *Villin-Cre-ERT2* ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Similar to the observations with elevated Dnmt3b, inactivation of Dnmt3b did not significantly affect the number of intestinal tumors at the time of terminal disease ([Figure 3](#fig3){ref-type="fig"}G). Again, no differences in tumor histology were noted either. However, inactivation of Dnmt3b did significantly extend survival of mice harboring *BrafV600E* ([Figure 3](#fig3){ref-type="fig"}H). Consistent with the previous elevated Dnmt3b model, these results suggest that abundance of Dnmt3b is rate-limiting for acquisition of a lethal burden of tumors in this BrafV600E-induced intestinal cancer model. Overall, these data support the notion that the combination of BrafV600E and elevated Dnmt3b can be potently oncogenic in CRC.

Activated BRAFV600E Repressed Expression of DNMT3b and Failed to Induce a CIMP Phenotype {#sec2.4}
----------------------------------------------------------------------------------------

According to a previously proposed model, activated BRAFV600E signaling recruits DNMT3B to genes silenced by CIMP via the transcriptional repressor, MAFG ([@bib12], [@bib13]). This model was based, in part, on the ability of BRAFV600E to increase expression of MAFG and decrease expression of CIMP target gene *MLH1* in primary human fibroblasts ([@bib12]). To extend this line of investigation, we ectopically expressed activated BRAFV600E in primary human fibroblasts and assessed its impact on DNMT3B and CIMP. As shown previously ([@bib35]), ectopic expression of BRAFV600E induced proliferation arrest and upregulation of markers of senescence ([Figures 2](#fig2){ref-type="fig"}A and [4](#fig4){ref-type="fig"}A). However, surprisingly, activated BRAFV600E triggered downregulation of DNMT3B expression ([Figure 4](#fig4){ref-type="fig"}A). Next, we set out to ask whether oncogenic BRAFV600E is able to induce methylation changes characteristic of CIMP. Primary human fibroblasts were again infected with a lentivirus directing expression of BRAFV600E. Seven days after infection, the cells were harvested, DNA prepared, and subject to WGBS to map the DNA methylome. Principal Component Analysis poorly separated the control and BRAFV600E-expressing cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Consistent with this, although we reported previously that replicative senescent (RS) cells undergo a marked global hypomethylation ([@bib7]), BRAFV600E-expressing cells showed only a very small overall gain in methylation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). A scatterplot of CpG methylation in control versus BRAFV600E-expressing cells also revealed no substantial differences, in contrast to a comparison of proliferating and replicative senescent fibroblasts, which revealed marked hypomethylation in the latter ([Figure 4](#fig4){ref-type="fig"}B) ([@bib7]). The relative similarity of vector and BRAFV600E cells, compared with proliferating versus replicative senescent, was underscored by whole chromosome difference plot ([Figure S4](#mmc1){ref-type="supplementary-material"}B). This revealed the marked hypomethylation of lamin-associated domains (LADs) in replicative senescent cells reported previously ([@bib7]), but this was absent from BRAFV600E cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Indeed, although many significantly differentially methylated individual CpGs and regions (DMRs) were detected between proliferating and RS cells, very few were detected between control and BRAFV600E-expressing cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Although increasing the window size of candidate DMRs decreased the number of DMRs detected in replicative senescent cells due to merging of small DMRs, varying the size of candidate DMRs did not majorly affect the number of DMRs detected in BRAFV600E cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Most relevant to a candidate CIMP-like phenotype, BRAFV600E-expressing cells did not gain methylation at CpG islands whose methylation is diagnostic of CIMP, including *MLH1, CACNA1G, CDKN2A, CRABP1,* and *NEUROG1;* this is in contrast to replicative senescent cells ([Figure 4](#fig4){ref-type="fig"}C) ([@bib7]). Taken together, these results do not support a role for BRAFV600E in direct induction of CIMP via DNMT3B, at least in fibroblasts.Figure 4Ectopic Expression of DNMT3B Does Not Induce CIMP(A) Western blot of lysates from human fetal lung fibroblasts (IMR-90) infected with lentivirus directing expression of BRAFV600E or corresponding empty vector. MW markers in kDa.(B) Scatterplot of CpG methylation in BRAFV600E-infected fibroblasts compared with proliferating "vector" controls (top), and replicative senescent (PD88) compared with proliferating controls (PD28) (bottom).(C) Smoothened methylation plots of CIMP panel genes in vector and BRAFV600E-expressing cells. Red and blue lines indicate the smoothened average percentage methylation at corresponding CpGs. Individual CpGs are indicated by black "ticks" along the x axis.

BRAFV600E Mutation Is Neither Necessary nor Sufficient for CIMP, and BRAFV600E Mutations and CIMP Are Both Linked to a Low Expression of DNMT3B {#sec2.5}
-----------------------------------------------------------------------------------------------------------------------------------------------

In light of these functional data, we turned again to human TCGA data to shed more light on the potential interactions between BRAFV600E and DNMT3B in human CRC. First, we clustered patient samples based on methylation values of all probes at CpG islands showing significant variance across the human TCGA CRC datasets. As expected, this separated out human CRC into at least three groups, one of relatively high methylation at CpG islands, CIMP high (CIMP-H), and CIMP low (CIMP-L) and non-CIMP ([@bib21], [@bib3]) ([Figure 5](#fig5){ref-type="fig"}A). As expected, and as reported previously ([@bib21], [@bib3], [@bib49], [@bib42]), CIMP-H tumors associated with *BRAFV600E* mutation ([Figure 5](#fig5){ref-type="fig"}A) (2.16-fold enrichment, p \< 0.001). Somewhat surprisingly, however, CIMP-H tumors were anti-correlated with *DNMT3B* copy number amplification ([Figure 5](#fig5){ref-type="fig"}A) (0.21-fold enrichment, p \< 0.001). The same relationship was apparent when we analyzed only samples with microsatellite instability (MSI+), known to be enriched in CIMP ([@bib17]) ([Figure S5](#mmc1){ref-type="supplementary-material"}A). To examine more closely the relationship between CIMP and *DNMT3B* amplification, we rank-ordered all human CRC samples by the degree of *DNMT3B* amplification (which correlates with expression ([Figures 1](#fig1){ref-type="fig"}C and 1D)) and compared with CIMP. Amplification of *DNMT3B* was not associated with CIMP and, indeed, the tumors with the most overt CIMP appeared to associate with relatively low *DNMT3B* copy number ([Figure 5](#fig5){ref-type="fig"}B). Next, we directly compared CIMP score with *DNMT3B* amplification or expression. This confirmed an inverse relationship between CIMP and both *DNMT3B* amplification and expression ([Figures 5](#fig5){ref-type="fig"}C, 5D, and [S5](#mmc1){ref-type="supplementary-material"}A). Finally, we directly compared *DNMT3B* expression and *BRAFV600E* mutation. This showed that *DNMT3B* expression is higher in those tumors with wild-type BRAF ([Figures 5](#fig5){ref-type="fig"}E, [S5](#mmc1){ref-type="supplementary-material"}C, and S5D). In sum, this analysis of human TCGA confirms the strong association between *BRAF* mutation and CIMP-H but does not support a marked association between amplification and increased expression of *DNMT3B* and either BRAF mutation or CIMP-H and so challenges the idea that elevated DNMT3B contributes to BRAFV600E-induced tumorigenesis and associated CIMP in humans.Figure 5Human BRAFV600E/CIMP Tumors Express Low Levels of DNMT3B(A) Clustering of TCGA human CRC based on Illumina 450K DNA methylation array data (all CpGs showing variation \>0.2 StdDev). *BRAF* mutation and *DNMT3B* amplification status are shown below (red = mutated/amplified).(B) CpG probes (y axis of the heatmap) clustered based on increasing *DNMT3B* copy number (x axis of the heatmap).(C) Relationship between *DNMT3B* copy number and methylation of CIMP biomarker genes (*CACNA1G, RUNX3, IGF2, MLH1, NEUROG1, CRABP1, CDKN2A*). Red line marks the boundary between non-amplified and amplified *DNMT3B*. Each black dot indicates the mean methylation score in the indicated probes in one patient sample. Y axis---mean methylation, x axis---relative copy number.(D) Boxplot of *DNMT3B* FPKM mRNA expression in human colorectal carcinoma TCGA patients subdivided by CIMP status. Mann Whitney test, p = 0.001.(E) Violin plot showing distribution of DNMT3B expression levels in 207 CRC tumor samples, separated according to *BRAF* WT or *BRAFV600E* mutant. p value = 0.0001.

Discussion {#sec3}
==========

Approximately 10% of human colorectal cancers harbor a *BRAFV600E* mutation, which has been demonstrated to act as a founder mutation for an alternative serrated pathway of colorectal carcinogenesis ([@bib3], [@bib14], [@bib48], [@bib16], [@bib4], [@bib41]). However, on its own, both *in vitro* and *in vivo*, activated oncogenic BRAFV600E induces OIS, an established tumour-suppressive mechanism ([@bib35], [@bib4], [@bib41], [@bib8]). Consistent with a potent BRAFV600E-induced tumor suppressor mechanism in humans, activating *BRAFV600E* mutations are detectable in 62%--70% of hyperplastic colonic polyps: lesions traditionally considered to harbor no oncogenic potential ([@bib53], [@bib34]). Furthermore, the existence of an OIS barrier in human serrated pathway carcinogenesis is supported by the published *in situ* data ([@bib25]).

It is clear, therefore, that additional genetic and/or epigenetic events are required to promote neoplastic transformation in the serrated pathway, which if untreated (e.g. by endoscopic polypectomy) eventually culminates in the development of invasive carcinoma. CIMP is thought to promote tumorigenesis by bypass of tumour-suppressor mechanisms, such as silencing of *CDKN2A/INK4A* ([@bib25], [@bib4]). It has been recognized for some time that there is an extremely close relationship between *BRAFV600E* mutations and CIMP-H in human colorectal cancer ([@bib39], [@bib49], [@bib23], [@bib36], [@bib37], [@bib21], [@bib3]). Although this association was initially correlative, it has recently been proposed that BRAFV600E can directly induce CIMP through the *de novo* methyltransferase, DNMT3B ([@bib12], [@bib13]). Separately, elevated DNMT3B expression has previously been linked to the development of CIMP in both murine and human colorectal neoplasia ([@bib4], [@bib22], [@bib38], [@bib45]). Furthermore, DNMT3B has been demonstrated to have an oncogenic function in murine colon cancer ([@bib30], [@bib31]). Thus, the emerging dogma is of a model in which neoplastic transformation in *BRAFV600E*-mutant colorectal serrated lesions may be contributed to by the ability of this oncogene to induce a CpG island methylator phenotype, mediated by DNMT3B.

There are, however, several obvious paradoxes. Firstly, only a minority of colorectal lesions harboring an activating *BRAFV600E* mutation eventually progress to invasive carcinoma ([@bib53], [@bib34]). Secondly, CIMP develops gradually with serrated pathway progression ([@bib23]). Thirdly, as many as 40% of CIMP-H tumors do not harbor an activating *BRAFV600E* mutation. Finally, approximately 10% of patients with an activating *BRAFV600E* mutation are CIMP-L or CIMP-negative ([@bib39]). Thus, a simple, linear model by which BRAFV600E directly induces CIMP cannot be fully reconciled with the disease biology. We therefore set out to comprehensively examine the relationships between an activated BRAFV600E oncogene, DNMT3B, and CIMP in colorectal cancer by multiple approaches.

Because activated BRAFV600E is a potent inducer of OIS ([@bib35], [@bib4], [@bib41], [@bib8]), we initially set out to test the idea that elevated DNMT3B can bypass BRAFV600E-induced OIS. Indeed, ectopic expression of DNMT3B together with BRAFV600E partially suppressed two phenotypes characteristic of BRAFV600E-induced OIS, namely proliferation arrest and, most notably, SASP. Extending these results *in vivo*, conditional inducible and knockout mouse models showed that expression of Dnmt3b is rate-limiting for accumulation of a lethal burden of BrafV600E-driven tumors in mouse intestinal epithelium. The molecular mechanisms underlying these phenotypes remain to be established. Conceivably, suppression of SASP gene expression by DNMT3B could depend on suppression of BRAFV600E signaling, *de novo* methylation of SASP genes, or another mechanism. Regardless of the specific mechanism, these *in vitro* and *in vivo* lines of evidence support an oncogenic function for DNMT3B in cooperation with BRAFV600E.

However, our other analyses do not support a role for DNMT3B cooperating with activated BRAFV600E via its induction of CIMP. Since activated BRAFV600E has been proposed to directly potentiate DNMT3B-mediated CIMP and silencing of tumor suppressor genes ([@bib12], [@bib13]), we wondered whether BRAFV600E-induced OIS might simultaneously sow the seeds of its own destruction, in the form of DNMT3B-mediated CIMP. However, in contrast to replicative senescent cells, in OIS BRAFV600E efficiently repressed expression of DNMT3B, and we observed very few BRAFV600E-induced DNA methylation changes. Finally, a closer examination of human TCGA data suggests that BRAFV600E and DNMT3B are unlikely to cooperate in tumorigenesis, and DNMT3B is unlikely to mediate CIMP. Analysis of data accessible through cBioportal, including TCGA and the largest study of 1,134 samples ([@bib51], [@bib15]), also indicates that *BRAFV600E* mutation and *DNMT3B* amplification tend to be mutually exclusive. Taken together, these *in vitro* and *in silico* studies suggest that in BRAFV600E-driven CRC, elevated DNMT3B is likely not the cause of CIMP, and BRAFV600E and DNMT3B are unlikely to cooperate in progression of this disease. In summary, the data presented herein challenge the current model of the relationships between BRAF, DNMT3B, and CIMP in human colorectal cancer, whereby DNMT3B contributes to CIMP in association with *BRAFV600E* mutation and, in the most extreme form of the model, that mutant-*BRAFV600E* drives CIMP via DNMT3B. By multiple approaches, *in vitro* and by *in silico* analysis of TCGA, we have demonstrated that BRAFV600E mutation is associated with and can cause repression of DNMT3B. Furthermore, although *DNMT3B* overexpression and somatic copy number amplification are common features of human colorectal cancer, they are inversely correlated with CIMP. In functional *in vitro* studies, we obtained no evidence that DNMT3B is a driver of CIMP. Thus, although BRAFV600E and DNMT3B both harbor oncogenic potential, they do not appear to cooperate to induce CIMP and do not appear to cooperate frequently in human colorectal cancer by any mechanism.

Limitations of the Study {#sec3.1}
------------------------

Of course, there are limitations to these conclusions drawn in part from "negative data" that we have been unable to address over the time frame of this study. First, although BRAFV600E does not induce detectable methylation changes characteristic of CIMP in a bulk population of cells, we cannot exclude the possibility that it does so in a very small subset of cells that is then prone to senescence escape, clonal outgrowth, and tumorigenesis. Even so, comparison of our WGBS data reported here for OIS with our previous studies in RS suggest that CIMP is more likely to arise in RS cells linked to other cumulative molecular stresses, e.g. telomere shortening, than in OIS cells ([@bib7]). Second, our analysis of human TCGA data does not preclude an association between DNMT3B expression and BRAFV600E at very early stages of disease, prior to detection and inclusion of tumors in the TCGA study. Although these limitations may go some way toward reconciling our conclusions with those of previous studies, it is important to note that prior functional studies most directly linking DNMT3B to CIMP have been performed in established colon cancer cell lines *in vitro* ([@bib12]). Despite these limitations to our study, we feel that, on balance, the weight of evidence does not support a role for DNMT3B and BRAFV600E cooperating in intestinal cancer.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

RNA-seq and DNA methylation data is available at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126434>. The accession number for the data reported in this paper is [GSE126434](ncbi-geo:GSE126434){#intref0020}: secure token for access exqpcwyshxsfdgd).

Supplemental Information {#appsec3}
========================

Document S1. Transparent Methods and Figures S1--S5
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